Summary:
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.
Qualified Participants Must:
• Be between 18 and 75 years of age (Adult, Senior)
•
Have migraine onset before age 50
Qualified Participants May Receive:
Study-related medical care and investigational drug at no cost and may be compensated for time and travel.